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Abstract Background and Objective: Stroke patients with severe leg paralysis are often
bedridden in the acute and subacute phase, which increases the risk of disuse
muscle atrophy in the chronic phase. The evidence to date indicates that
oxidative stress plays an important role in the mechanism of disuse muscle
atrophy. Therefore, the aim of this study was to determine if long-term rad-
ical scavenger treatment with edaravone following an acute stroke prevents
the progression of disuse muscle atrophy and improves leg locomotor func-
tion in the chronic phase.
Methods: This randomized controlled pilot study was conducted at 19 acute
stroke and rehabilitation centers across Japan. Forty-seven ischemic stroke
patients with at least leg motor weakness admitted within 24 hours of onset
were randomly assigned to receive continuous intravenous infusions of
edaravone 30mg twice daily for 3 days (short-term group) or 10–14 days
(long-term group). The primary endpoints of the study included the degree of
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leg disuse muscle atrophy, as measured by the percentage change from
baseline in femoral muscle circumference 15 cm above the knee, and the im-
provement in leg locomotor function, as assessed by the maximum walking
speed over 10m, 3 months after the onset of stroke.
Results: Three-month follow-up was completed by a total of 41 patients (21 in
the short-term group and 20 in the long-term group). On admission, there was
no significant difference in the severity of stroke or the grade of leg paresis
between the two treatment groups. The grade of disuse muscle atrophy and
incidence of gait impairment 3 weeks after stroke onset were also similar
between the short- and long-term groups. However, disuse muscle atrophy of
the paretic and non-paretic legs was significantly less severe in the long-term
versus the short-term treatment group (3.6 – 5.9% and 1.5 – 6.0% vs
8.3 – 5.2% and 5.7 – 6.4%; p < 0.01 and p < 0.05) 3 months after stroke onset.
Additionally, the maximum walking speed over a distance of 10m was signi-
ficantly greater in the long-term group (98 – 67 vs 54– 55 cm/sec; p < 0.05).
Conclusion: Edaravone treatment for up to 14 days suppresses the progres-
sion of disuse muscle atrophy and improves leg locomotor function to a
greater extent than shorter-term treatment in acute stroke patients. This
suggests that the management of stroke may be improved with long-term
edaravone therapy by providing myoprotective effects that ameliorate func-
tional outcome in the chronic phase.
Introduction
Stroke is a global health problem and is a
major cause of death and disability in the adult
population.[1] One of the most common symp-
toms of stroke is motor weakness, which can lead
to considerable disruption of activities in daily
life such as feeding, bathing, dressing, and groom-
ing. During a cerebral infarction, motor tracts in
the frontal cortex, the corona radiata, the internal
capsule, or the pons are often impaired, resulting
in the development of hemiparesis of the lower
limbs and subsequent leg locomotor dysfunction
during the chronic phase of stroke.[2]
However, leg locomotor dysfunction is not
solely attributable to ischemic cerebral damage of
motor neuron tracts, but may also be in part
due to disuse muscle atrophy of both paralyzed
and non-paralyzed legs. Indeed, a small study of
healthy older adult subjects demonstrated that 10
consecutive days of bed rest caused substantial
losses in skeletal muscle mass and function, par-
ticularly in the lower extremities.[3] Acute stroke
patients with severe hemiparesis or paralysis can
remain bedridden for at least 1–2 weeks, and are
often unable to walk despite weeks of rehabilita-
tion. This extended period in a bedridden state
during the acute and subacute phases of stroke is
the likely cause of lower limb disuse muscle atro-
phy in association with leg motor weakness, thus
accelerating the development of leg locomotor
dysfunction in the chronic phase.[4,5]
The involvement of oxidative stress in disuse
muscle atrophywas first highlighted in the 1990s.[6-8]
Although the exact mechanisms of disuse muscle
atrophy in humans remain unclear, the evidence
to date has established the important role that
oxidative stress plays in the development of dis-
use muscle atrophy.[9,10] The free radical scaven-
ger edaravone is a neuroprotective drug that
has been indicated for the treatment of acute
stroke since 2001 in Japan, and has been shown to
dose dependently improve functional outcomes in
patients with acute ischemic stroke.[11-13] Edaravone
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can donate an electron to a lipid peroxyl radical,
which results in conversion to a lipid peroxyl
anion.[14] Edaravone scavenges free radicals pro-
duced by activation of the arachidonic acid cas-
cade during cerebral ischemia-reperfusion, and
inhibits the peroxidation of lipids by free radi-
cals.[14] Edaravone has been shown to protect the
vascular endothelium and reduce damage to
neuronal and glial cells by scavenging for free
radicals.[14-17]
In Japan, the recommended duration of edar-
avone administration is 14 days, but this can be
shortened in patients with mild symptoms.[18]
Early studies indicated that neuronal cells cannot
survive for more than several hours after ische-
mia and that cell-killing events continue for a few
days. These studies suggest that neuroprotective
drugs may exert protective effects if started
within several hours after ischemia and continued
for a few days.[19,20] Based on these findings, a
3-day administration of edaravone is considered
sufficient to exert adequate cerebroprotection.
However, Unno et al.[12] reported that the dura-
tion of edaravone therapy affected the functional
outcome in acute ischemic stroke patients. More-
over, animal studies indicate that the process of
radical-related disuse muscle atrophy begins sev-
eral days after leg immobilization.[6-10] This sug-
gests that radical scavenger therapy should be
administered for a longer period when used to
suppress the development of radical-related dis-
use muscle atrophy.
The aim of the present pilot study entitled
MARVELOUS (Muscular Atrophy Restraint
with Vigilant Edaravone Long-term Use after
Stroke) was to determine if long-term treatment
with the free radical scavenger edaravone can
(i) suppress disuse muscle atrophy following an
acute stroke; and (ii) alleviate the degree of gait
impairment during the chronic phase.
Patients and Methods
Patients
Nonconsecutive acute stroke patients admit-
ted to an acute stroke center within 24 hours of
onset were eligible for the study. Inclusion criteria
were age 20–79 years, the presence of a leg motor
weakness rating of 2–4 on the National Institute
of Health Stroke Scale (NIHSS) motor subscore
on admission, and no apparent functional dis-
ability prior to stroke as estimated by a modified
Rankin Scale (mRS) score of 0 or 1. Exclusion
criteria were a history of hypersensitivity to
edaravone, associated neuromuscular diseases,
obstructive femoral artery diseases, congestive
heart failure, significant renal/hepatic diseases,
hemorrhagic stroke, use of thrombolytic therapy,
a Japan Coma Scale score of 20 or more, history
of neurologic dysfunction with an mRS score of
‡2, artificial knee or hip joints, serum creatinine
>1.5mg/dL, malignant disorders, pregnancy, or
enrollment in another clinical study.
The study was approved by the local ethics
committee of each participating institute and was
conducted in accordance with the World Medical
Association Declaration of Helsinki and the
Ethical Guidelines for Epidemiological Research
of the Japanese Ministry of Education, Culture,
Sports, Science and Technology, and the Japanese
Ministry of Health, Labour and Welfare. All pa-
tients provided written informed consent prior to
entry into the study and were centrally registered
via the Internet.
Study Design
The study was an open-label, randomized,
controlled pilot study that was conducted in 19
institutes comprising 13 acute stroke centers and
six rehabilitation centers in Japan. A central as-
signment/registration method via the Internet
was used for case registration and allocation; pre-
registered individual identification and password
was used for verification. Input included the time
of hospital admission, name of the hospital, age,
sex, severity (an NIHSS motor subscore of the
hemiparetic lower limb), and name of the person
who input the data.
Randomizationwas performedwith control fac-
tors of the name of the hospital, age, sex, and an
NIHSS motor subscore of the hemiparetic lower
limb, and the cases were divided into two groups
with a ratio of 1 : 1. Patients were randomized to
receive edaravone (30mg twice daily), adminis-
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tered intravenously for 3 days (short-term group)
or 10–14 days (long-term group).
All patients were admitted to an acute stroke
center and underwent bedside rehabilitation
therapy, followed by out-of-bed rehabilitation
therapy. The start time of rehabilitation ther-
apy was classified into four categories: (i) on the
day of admission; (ii) within 3 days of admission;
(iii) within 7 days of admission; and (iv) 8 or more
days after admission. Following the completion
of acute-phase rehabilitation therapy, patients
were transferred to a post-stroke rehabilitation
center.
It should be noted that physicians from the
acute stroke center were responsible for follow-up
evaluations of leg muscle volume and locomotor
function at 3 weeks and/or 3 months post-stroke
in patients who were transferred to a rehabili-
tation center that was not affiliated with the
MARVELOUS Study Group. In contrast, pa-
tients transferred to a MARVELOUS-affiliated
rehabilitation center were evaluated by a physi-
cian from the rehabilitation center.
Procedures
Edaravone (Radicut, Mitsubishi Tanabe
Pharma Corporation, Osaka, Japan) administra-
tion was started upon admission. Patients re-
ceived edaravone 30mg twice daily, which was
dissolved in 100mL of saline and administered by
continuous intravenous infusion for 30minutes.
Edaravone was administered for 3 consecutive
days in the short-term group and 10–14 consec-
utive days in the long-term group.
Assessment of Study Endpoints
The primary endpoints of the study included
changes from baseline in the degree of leg disuse
muscle atrophy and the severity of leg locomotor
dysfunction 3 months after the onset of stroke.
Leg disuse muscle atrophy was defined as a re-
duction (expressed as a percentage) from baseline
(within 4 days of admission) in femoral muscle
volume at 3 weeks and 3months after the onset of
stroke, which was assessed by measuring the
femoral muscle circumference of both legs at 5,
10, and 15 cm above the knee when patients were
in a supine position with both legs outstretched.
The severity of locomotor dysfunction was eval-
uated based on the Brunnstrom Recovery Stage
(BRS)[21] and maximum walking speed (MWS)
over a distance of 10m.
Statistical Analysis
According to unpublished data from our pre-
liminary study of ischemic stroke patients un-
dergoing edaravone treatment, ‘good’ locomotor
function (mRS 0–2) 3 months after stroke onset
was seen in 17% and 60% of patients receiving
3 and 14 days of edaravone therapy, respectively.
Based on these findings, sample size calculations
using a power of 80% indicated that a minimum
of 38 patients was required to detect a difference
in the primary endpoint, assuming a two-sided
significance level of 0.05.
Data were expressed as percentages for cate-
gorical variables or means for continuous varia-
bles. A Pearson’s chi-squared (w2) or Fisher’s exact
test was used for the statistical comparison of
categorical variables. An unpaired Student’s t-test
was also used to compare differences in the de-
gree of disuse muscle atrophy and MWS between
the two groups. Furthermore, simple regression
analysis was undertaken to assess the correla-
tion between the degree of paralyzed leg muscle
atrophy and MWS. A p-value of <0.05 was con-
sidered to be statistically significant. Statistical
analyses were carried out usingMicrosoftOffice
Excel 2003.
Results
A total of 47 eligible patients were registered
into the study during the 1-year period from
1 January 2007 to 31December 2007. Three-month
follow-up was successfully completed by 41 of
47 patients; data from these 41 patients were in-
cluded in the analysis. The six patients who did
not complete the 3-month follow-up were ex-
cluded from the analysis for the following rea-
sons: the development of cerebral hemorrhage
during the follow-up period (n = 1); discontinua-
tion of edaravone due to the occurrence of liver
disorders during treatment (n = 1); inability to
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continue the drug infusion for more than 1 day
because of heart failure (n = 1); no rehabilitation
was performed during the follow-up period due
to associated pneumonia and other complica-
tions (n = 1); and discontinuation of follow-up
for personal reasons (n = 2). Consequently, the
analysis was performed in 21 patients in the
short-term (3 days of edaravone therapy) group
and 20 patients in the long-term (10–14 days of
treatment) group.
Table I shows a detailed summary of patient
characteristics of the two study groups. There
was no significant difference in age, sex, risk fac-
tors, stroke subtypes, severity of stroke as defined
by the NIHSS score, or the grade of leg paresis
on the affected side as defined by the NIHSS
motor subscore. All patients in the short-term
group received 3 days of edaravone treatment;
the mean – standard deviation duration of edar-
avone treatment in the long-term group was
13.6 – 1.2 days.
Table II compares the state of rehabilitation
therapy in the acute phase, the incidence of gait
disability 3 weeks after stroke onset, and the se-
verity of leg disuse muscle atrophy 3 weeks after
stroke onset between the short- and long-term
edaravone treatment groups. The time of ini-
tiation of bedside and out-of-bed rehabilitation
therapy and the total days of rehabilitation were
similar between the two treatment groups. Gait
disability 3 weeks after stroke onset was defined
as confinement to a wheelchair or a bedridden
state, and was reported in 47.6% and 45.0% of
patients in the short- and long-term groups, re-
spectively. The severity of disuse muscular atro-
phy in the paretic and non-paretic legs (measured
15 cm above the knee) was numerically greater in
the short-term group (5.0 – 3.4% and 3.7 – 4.4%,
respectively), compared with the long-term group
(4.4 – 4.1% and 2.0 – 3.8%, respectively) 3 weeks
after stroke onset, but this difference was not
statistically significant.
The effect of edaravone treatment on the grade
of leg disuse muscle atrophy and the level of
leg locomotor function during the chronic phase
(3 months after the onset of stroke) is summar-
ized in table III. The grade of disuse muscle atro-
phy (i.e. percentage reduction from baseline in
femoral muscle volume) in the paretic and non-
paretic legs at 15 cm above the knee was signif-





Age (y) [mean –SD] 70.0 – 7.3 69.2 –7.5
Sex (n, M/F) 13/8 14/6
Risk factors [n (%)]
hypertension 17 (80.9) 16 (80.0)
diabetes mellitus 8 (38.1) 7 (35.0)
dyslipidemia 7 (33.3) 8 (40.0)
atrial fibrillation 3 (14.3) 5 (25.0)
Stroke subtype [n (%)]
cardioembolic 3 (14.3) 4 (20.0)
atherothrombotic 13 (61.9) 12 (60.0)
lacunar 5 (23.8) 4 (20.0)
Duration of study treatment (days) [mean –SD] 3.0 – 0.0 13.6 – 1.2
NIHSS score on admission [median (range)] 7 (3–24) 9 (2–19)
NIHSS motor subscores [median (range)] 3.0 (2–4) 2.5 (2–4)
Severe leg weaknessb [n (%)] 11 (52.4) 10 (50.0)
a Data for 41 patients who completed the study.
b Severe leg weakness was defined as an NIHSS motor subscore of 3–4.
F = female; M =male; NIHSS =National Institute of Health Stroke Scale.
Effects of Edaravone on Muscle Atrophy and Locomotor Function 159
ª 2010 Naritomi et al., publisher and licensee Adis Data Information BV. Drugs R D 2010; 10 (3)
icantly less severe in the long-term group, com-
pared with the short-term group (3.6 – 5.9% and
1.5 – 6.0% vs 8.3 – 5.2% and 5.7 – 6.4%; p < 0.01
and p< 0.05). A similar trend in disuse muscle
atrophy was also seen when assessed at 5 and
10 cm above the knee (data not shown).
Long-term treatment with edaravone was
associated with a significant improvement in
leg locomotor function, as measured by MWS
(97.9 – 67.3 vs 53.6 – 54.8 cm/sec; p < 0.05 vs the
short-term group). A larger proportion of pa-
tients in the long-term group also reported good
leg locomotor function than the short-term group
(70.0% vs 57.1%), as defined by a BRS of 5–6, but
this difference was not statistically significant.
Finally, there was a significant negative correla-
tion between the severity of disuse muscle atro-
phy in the paretic leg and MWS (r = –0.87;
p < 0.001) [figure 1].
Discussion
The free radical scavenger edaravone is cur-
rently the only cerebroprotective agent to be ap-
proved for clinical use in the management of acute
stroke, and has been shown to improve func-
tional outcome in Japanese patients with acute
ischemic stroke.[11-13] During the last decade of
the 20th century, at least 30 substances with cere-
broprotective action were subjected to phase III
clinical trials of acute stroke patients; these stud-
ies produced negative results on improved clini-
cal efficacy with the exception of edaravone.[22-24]
However, the clinical data on edaravone should






bedside within 3 days of admission [n (%)] 14 (66.7) 14 (70.0)
out-of-bed within 7 days of admission [n (%)] 7 (33.3) 11 (55.0)
total duration (days) 16.0 –5.0 16.4 –7.3
Gait disabilityb 3 weeks after stroke onset [n (%)] 10 (47.6) 9 (45.0)
Disuse muscle atrophy (%)c
paretic leg 5.0 –3.4 4.4 –4.1
non-paretic leg 3.7 –4.4 2.0 –3.8
a Values are expressed as mean – standard deviation unless stated otherwise.
b Gait disability was defined as patients in a wheelchair or bedridden state, with a National Institute of Health Stroke Scale (NIHSS) motor
subscore of 3–4.
c Disusemuscle atrophy was expressed as amean percentage reduction from baseline in femoral muscle volume (i.e. muscle circumference
measured 15 cm above the knee).





Disuse muscle atrophy (%)b
Paretic leg 8.3 – 5.2 3.6 –5.9**
Non-paretic leg 5.7 – 6.4 1.5 –6.0*
Level of leg locomotor function
Patients with BRS 5–6 [n (%)] 12 (57.1) 14 (70.0)
MWS (cm/sec) 53.6 – 54.8 97.9 –67.3*
a Values are expressed as mean – standard deviation unless stated otherwise.
b Disusemuscle atrophy was expressed as amean percentage reduction from baseline in femoral muscle volume (i.e. muscle circumference
measured 15 cm above the knee).
BRS =Brunnstrom Recovery Stage; MWS =maximum walking speed; * p< 0.05 vs short-term group, ** p <0.01 vs short-term group.
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be interpreted with caution due to a number of
major differences in the design of the trial con-
ducted on edaravone, compared with those of
other cerebroprotective agents. First, edaravone
could be administered within 72 hours of stroke
onset, but this was restricted to within 6–12 hours
of onset in studies involving other cerebropro-
tective agents. Secondly, the infarct size was
generally smaller in the edaravone study, which
resulted in minor neurologic symptoms such as
motor weakness; various higher cortical dys-
functions occurred in other studies that included
patients with larger infarcts. Finally, edaravone
could be administered for a duration of up to
14 days, compared with 1–3 days in other studies
such as the SAINT (Stroke Acute Ischemic
NXY-059 [Cerovive] Treatment) II trial.[25]
The results of the phase III clinical study on
edaravone suggest that the beneficial effects of
the drug may also be partly attributable to myo-
protective effects.[11] Based on this hypothesis,
we conducted the present pilot study to determine
the myoprotective effects of edaravone in acute
stroke patients. In the present study, patients
were randomly allocated to edaravone therapy
for a 3- or 14-day duration; this latter duration of
administration was thought to be sufficient to
provide both cerebroprotective and myoprotec-
tive effects.
Disuse muscle atrophy is a phenomenon that
is seen in clinical practice when patients are in a
long-term bedridden state or during prolonged
rest with restricted activity and/or mobility. The
atrophy of skeletal muscle arises from the reduc-
tion or atrophy of myofibers.[9,10] Although the
exact mechanism of onset of disuse muscle atro-
phy remains unclear, we reported experimental
results that indicated a close relationship between
oxidative stress and disuse muscle atrophy.[6-8]
More specifically, atrophic muscles of rats showed
elevated levels of thiobarbituric acid reactive
substances and oxidized glutathione, which are
both markers of oxidative stress. Furthermore,
an increase in the formation of superoxide radi-
cal anions (O2
-) was indicated by elevated Cu/Zn-
containing superoxide dismutase activity in the
cytoplasm of atrophic muscle cells, and 12 days of
disuse atrophy showed a 2.2-fold rise in xanthine
oxidase levels relative to controls. Indeed, histo-
chemical studies using transmission electron mi-
croscopy revealed elevated levels of reactive
oxygen species such as H2O2 in atrophic mus-
cles.[6-8] Metals such as iron have also been shown
to increase oxidative stress in atrophic muscle,
and the administration of the iron-chelating
agent deferoxamine suppressed the increase in
thiobarbituric acid reactive substances and oxi-
dized glutathione in the atrophic muscles of
rats.[26] In recent years, the role of iron in oxida-
tive stress has attracted close attention in the field
of physiology.[9,10]
Another factor that may be involved in the
development of muscular atrophy is the elevation
of intracellular calcium ion (Ca2+) levels during
muscle inactivity.[6-8] Ca2+ levels in the cytoplasm
of atrophic muscle cells were approximately
4-fold higher than levels in normal muscle cells.
This accumulation of intracellular Ca2+ during
muscular disuse may occur due to ionic dis-
turbances of the cell membrane, which retards
cellular removal of Ca2+. This resulting elevation
of cytosolic Ca2+ may lead to the activation of
calcium-dependent proteases, thus leading to the
breakdown of muscle tissue.
In addition to inducing muscle atrophy during
disuse, oxidative stress has been shown to be en-
hanced during recovery from atrophy in rats.[27]
This suggests that the production of free radi-
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Fig. 1. Relationship between the severity of muscular atrophy in the
paretic leg and maximum walking speed (MWS). MWS decreases in
correlation with increases in the grade of the paralyzed leg atrophy
(r= -0.87; p <0.001). Thus, the atrophy provides significant negative
effects on the walking ability.
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recovering from disuse muscle atrophy. In the
present study, the continuous administration of
the free radical scavenger edaravone for an ex-
tended period of 14 days was beneficial in pa-
tients undergoing disuse muscle therapy, many of
whom started out-of-bed rehabilitation follow-
ing several days of bed rest. Therefore, a 2-week
treatment period of edaravone appears to be ef-
fective during both the period of muscle disuse
and the period of recovery of muscle activity.
The severity of muscle atrophy did not dif-
fer markedly between the two treatment groups
3 weeks after stroke onset in the present study,
but showed a significant improvement in favor of
the long-term treatment group after 3 months.
This may be explained by the delayed involve-
ment of apoptosis during the course of disuse
muscle atrophy, which eventually leads to muscu-
lar cell shrinkage and/or death.[9,10] As a result,
the clinical manifestation of muscle atrophy may
not become apparent until changes in the muscu-
lar intracellular environment have taken place,
which may occur over a period of several weeks.
The limitations of the present study include its
small sample size and lack of a placebo or control
group (i.e. standard therapy minus edaravone).
Another limitation was the inability to indepen-
dently assess the cerebroprotective and myopro-
tective effects of edaravone. An experimental
study utilizing a rat middle cerebral artery oc-
clusion model reported cellular oxidative damage
in the rat brain is evident for at least 7 days.[28]
Furthermore, the time to blood reflow in humans
with cerebral infarction varied according to the
occluded blood vessel and stroke subtype.[29]
These studies suggest the duration of the dis-
turbance caused by oxidative stress varies, and
there is a possibility that the observed benefits on
disuse muscle atrophy in the long-term group
may be partly attributable to a more potent cere-
broprotective effect of edaravone. If this is in-
deed the case, then the widely accepted view that
the process of ischemic neuronal cell death is al-
most completed within 2–3 days of stroke onset
should be reconsidered, and further clinical re-
search investigating the administration of cere-
broprotective agents for longer periods should be
conducted.
Conclusion
The results of our study indicated that treat-
ment with the free radical scavenger edaravone
for 14 days effectively improved both the severity
of disuse muscle atrophy and leg locomotor dys-
function in the chronic phase. Based on these
findings, the use of antioxidant therapy for as
long as possible appears to be warranted to pro-
vide the maximal level of both cerebroprotection
and myoprotection. Larger, randomized con-
trolled clinical trials are required to confirm the
beneficial effects of edaravone in the manage-
ment of stroke.
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